-- クリソス（ASX:C79）は、鉱石サンプル分析技術「フォトンアッセイ」の導入を2027年度に向けて加速させるため、今年に入ってから新たに19件のリース契約を締結したと、月曜日にオーストラリア証券取引所に提出した書類で明らかにした。 同社は2026年度の業績見通しを維持し、売上高は8,000万豪ドルから9,000万豪ドルの予測レンジの上限付近で推移しており、金利・税金・減価償却費・償却費控除前利益（EBITDA）も2,000万豪ドルから2,700万豪ドルの予測レンジの上限付近で推移していると述べた。 クリソスの株価は、月曜日の取引で1%上昇した。
Related Articles
International
Malaysia's Manufacturing Expands at Four-Year High as Prices Hit Record, S&P Global Says
Malaysia's manufacturing sector expanded at its fastest pace in four years in April, supported by stronger output and a return to growth in new orders, according to data released Monday by S&P Global.The S&P Global Malaysia Manufacturing Purchasing Managers' Index rose to 51.6 in April from 50.7 in March, marking a second straight month of expansion.Output grew at the fastest pace since December 2021, while new orders increased as firms and clients built safety stocks amid uncertainty linked to the Middle East war.Export orders declined for a second month, with firms citing weaker external demand tied to the conflict.Purchasing activity and employment increased, while supplier delivery times lengthened at the sharpest rate in nearly four years, leading to a further decline in pre-production inventories.Input costs rose to a 45-month high, driven by higher energy and material prices linked to the war, while selling prices increased at a record pace.Business confidence eased to an eight-month low, with firms citing uncertainty surrounding the Middle East conflict.
$^KLSE
Research
Research Alert: CFRA Maintains Sell Opinion On Ads Of Stellantis N.v.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We reduce our 12-month target price to USD5.80 from USD6.50, which implies a 2027 P/E of 3.5x. The reduction reflects a more cautious earnings outlook following Q1 2026 results, which, while marking a return to profitability, fell short of the pace of recovery we had previously modeled, particularly in the Enlarged Europe segment where persistent pricing headwinds are offsetting volume gains from the Smart Car roll-out. Consequently, we lower our 2026 EPS estimate to EUR0.90 from EUR1.37 and our 2027 estimate to EUR1.43 from EUR2.03. These downward revisions incorporate a larger-than-expected residual drag from prior-year cash charges, tariff impact that will continue to compress North American margins, and a European competitive environment. The sharp cut to our 2027 forecast also acknowledges that the path to a positive free cash flow inflection will demand flawless execution of an ambitious product cadence and cost discipline that the company has yet to demonstrate consistently.
$STLA
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Stryker Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $360 from $438, 21.5x our 2027 EPS forecast, below SYK's 10-year historical average of 24.5x. We maintain our 2026 EPS forecast at $14.94 and our 2027 EPS estimate at $16.71. We think that Stryker's Q1 results were significantly impacted by the late-quarter cyber incident that caused global business disruptions, leading to a miss on both revenue and earnings estimates. Despite disruptions affecting manufacturing, shipments, and revenue recognition, management maintained the full-year 2026 guidance of 8% to 9.5% Y/Y organic sales growth and adjusted EPS in the range of $14.90 to $15.10, expecting to recover most lost sales, which we find encouraging. Key catalysts for the remainder of the year include the proposed acquisition of Amplitude Vascular Systems, which has the potential to expand Stryker's cardiovascular capabilities and the creation of a new Ortho Tech business, which could streamline innovation and customer experience, in our view.
$SYK